Compare ADMA Biologics Inc (ADMA) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Hormel Foods Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Hormel Foods Corp trades at $24.61 (market cap $13.59B). The key difference: Hormel Foods Corp is far larger — about 6.4× ADMA Biologics Inc's market cap, and Hormel Foods Corp pays a 4.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HRL | |
|---|---|---|
Market Cap | $2.13B | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $31.54 |
52-Week Low | $7.60 | $19.74 |
Enterprise Value | $2.20B | $15.59B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Hormel Foods (HRL) trades at $24.70, down 1.2% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock has consistently beaten earnings estimates in recent quarters, though net income margin has compressed to 3.82%. Recent corporate actions include steady $0.29 dividends, while the company sold its Brazilian Ceratti operations to sharpen international focus. Analyst consensus price target is $25.00, slightly above current levels.
HRL offers a stable dividend profile as a Dividend King but faces margin pressure and modest growth. Near-term upside appears limited given current valuation and mixed analyst ratings. Key risks include input cost inflation and competitive pressures in the consumer staples sector. The stock presents a defensive income opportunity rather than significant capital appreciation potential in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
